Gts Securities LLC Neurocrine Biosciences Inc Put Options Transaction History

Gts Securities LLC

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $973,930 - $1.3 Million	8,500 Added 85.86%	18,400 $2.12 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.3 Million - $1.42 Million	9,900 New	9,900 $1.36 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $254,567 - $318,624	-2,400 Reduced 54.55%	2,000 $263,000
Q3 2023 Nov 15, 2023	BUY	$94.02 - $117.1 $413,688 - $515,240	4,400 New	4,400 $495,000

629

94.2M

692K

406K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.